Key Highlights
- Eli Lilly shares gained over 4% during early Monday trading following the release of promising clinical trial data over the weekend.
- The company’s advanced obesity treatment retatrutide demonstrated a 60.6% reduction in sleep apnea severity and achieved up to 73.1% improvement in knee pain during Phase 3 clinical trials.
- Data from 1,500 trial participants revealed that Lilly’s Foundayo oral medication produced weight loss outcomes in women throughout all menopause stages.
- Novo Nordisk announced Wegovy reached 3 million prescriptions since January — yet shares declined 3% in early European market activity.
- Over the past year, Eli Lilly shares have climbed 47%; Novo Nordisk has declined more than 40% during the same timeframe.
Eli Lilly delivered a flurry of clinical developments over the weekend. The pharmaceutical giant unveiled multiple positive trial outcomes on Saturday and Sunday, prompting an immediate investor response Monday morning — driving LLY shares upward by more than 4% in premarket hours, securing its position as the S&P 500’s second-strongest performer after Micron.
The spotlight fell on retatrutide, Lilly’s investigational next-generation weight management medication. Phase 3 clinical data unveiled at the American Diabetes Association conference in New Orleans demonstrated that the weekly injectable treatment reduced moderate-to-severe obstructive sleep apnea severity by 60.6% in obese adult participants.
Identical trial data revealed retatrutide achieved up to 73.1% reduction in knee osteoarthritis pain.
These findings complement previously disclosed data from Lilly demonstrating that obese patients achieved 28% body weight reduction with the medication, while adults living with type 2 diabetes experienced significant blood sugar level improvements.
Retatrutide represents Lilly’s innovative “triple G” therapeutic approach — it activates GLP-1, GIP, and glucagon receptors, positioning it beyond existing dual-mechanism medications like Zepbound, which already has sleep apnea approval.
Within one study, 2% of diabetic patients receiving the minimum dose experienced major adverse cardiovascular events. Lilly emphasized these incidents weren’t definitively attributed to the medication. Complete findings appeared in the Lancet on Saturday.
Foundayo Expands Treatment Potential
The weekend data releases continued beyond retatrutide. On Sunday, Lilly published analysis demonstrating its oral medication Foundayo correlated with weight reduction in women across every menopause phase. The conclusions derived from 1,500 women participating in the company’s ATTAIN-1 and ATTAIN-2 Phase 3 clinical studies.
This represents a substantial broadening of the medication’s addressable patient population, encompassing pre-menopausal, perimenopausal, and post-menopausal women.
Novo Reported Positive Developments — Market Reaction Remained Negative
Novo Nordisk similarly delivered encouraging news on Monday. The Danish pharmaceutical company announced its Wegovy obesity pill has now surpassed 3 million prescriptions since oral formulation availability in early January — averaging one new prescription every five seconds.
Novo characterized it as among the most significant U.S. pharmaceutical product launches in recorded history.
Yet investors remained unimpressed. Novo shares dropped 3% during early European trading hours, with its American depositary receipts indicating a 1.8% decline before U.S. market opening. The Danish exchange was closed Friday, explaining some of Monday’s price adjustment.
Novo’s shares have experienced challenging performance, declining more than 40% throughout the past year. Lilly, conversely, has advanced 47% across the identical period.
LLY traded approximately 4% higher Monday morning as the newest data wave continued strengthening its competitive position in the obesity medication market.
